Dimerix adds second drug to development suite
Dimerix (ASX:DXB) has added a second development program to the deck, with DMX-250 targeting fibrosis in patients with non-alcoholic steatohepatits – and it’s already had promising results.
DXB told its shareholders yesterday that in addition to the DMX-200 program under development to help sufferers of chronic kidney disease, that it was now investigating using a combination of angiotensin receptor blockers and propagermanium.
This combination was discovered using DXB’s proprietary screening assay, termed Receptor-Heteromer Investigation Technology (Receptor-HIT) – the same method used to identify DMX-200 and formed the basis of an internal drug development program, initially for the treatment of a subset of patients with chronic kidney disease.
DMX-250 will be developed with an eye towards curing non-alcoholic steatohepatitis, which carries the risk of progression into liver fibrosis and ultimately hepatocellular carcinoma – or liver cancer.
There is no established treatment for the disease, and it’s estimated that 6 million people are suffering from it in the US alone.
According to DXB, DMX-250 has had a positive effect while being used in a mouse model – warranting further investigation.
Investors should note that this is a very early stage drug and there is no guarantee of success – investors are advised to seek out the advice of a professional before investing.
In any case, the new drug adds a second drug onto the development schedule for DXB to augment its work in DMX-200.
It added that it was in the process of developing further pre-clinical studies for DMX-250.
About DXB and DMX 200
DXB has been hard at work progressing the DMX-200 drug through clinical trials in Melbourne.
The aim is to demonstrate that DMX-200 can safely reduce the level of proteinuria in the body.
Proteinuria is the presence of abnormal levels of protein in urine, which can be an indicator of chronic kidney disease in a patient.
Reducing proteinuria lowers the chances of CKD progression and its consequences such as the loss of renal function, and the development and progression of cardiovascular disease.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.